Hemolytic Disease of the Fetus and Newborn (Online Course)

(based on 888 customer ratings)

Author: Pat Letendre, MEd
Reviewer: Erin Tretter, MT(ASCP)

This course presents current information related to hemolytic disease of the fetus and newborn (HDFN). It provides you with an opportunity to review and update your knowledge of significant aspects of HDFN and its laboratory investigation and prevention. This course provides a broad overview of many important topics including causative antibodies, laboratory findings in severe HDFN, and pre- and postnatal treatments. Rh immune globulin (RhIg) is covered in depth, since it prevents the most severe form of HDFN and is one of the biggest success stories of modern medicine.

See all available courses »

Continuing Education Credits

  • P.A.C.E.® Contact Hours: 2 hour(s)
  • Florida Board of Clinical Laboratory Science CE - General (Blood Banking / Immunohematology): 2 hour(s)

Objectives

  • Describe and interpret typical clinical symptoms and associated laboratory test results in hemolytic disease of the fetus and newborn (HDFN) and relate findings to the pathogenesis of HDFN and its treatment.
  • Describe the progression of HDFN due to anti-D historically and discuss the effect of Rh immune globulin (RhIG) and other factors on its incidence.
  • Compare and contrast ABO HDFN and HDFN due to anti-D and other antibodies in terms of clinical symptoms, fetal monitoring procedures, laboratory investigation, typical test results, and criteria for donor RBC transfusions.
  • Identify current best practices for perinatal testing programs and investigation of HDFN and interpret serologic tests done on the mother, father, and fetus / newborn.
  • Discuss the criteria for administration, dosage calculation, and causes of failures of RhIG.
  • Describe the principles, uses, and limitations of the rosette test, Kleihauer-Betke test, and flow cytometry used in perinatal testing programs.

Customer Ratings

(based on 888 customer ratings)

Course Outline

  • Pathophysiology of HDFN and Blood group systems most commonly implicated in the disease
      • Introduction
      • Development of Anti-D
      • Factors That Affect Production of Anti-D
      • Primary versus Secondary Response
      • Pathophysiology in Severe HDFN Due to Anti-D
      • HDFN Due to Anti-D
      • ABO HDFN
      • ABO HDFN: Diagnostic Tests
      • ABO HDFN: Expected Findings
      • ABO HDFN: Treatment
      • ABO incompatibility between a D-negative mother and a D-positive fetus eliminates the possibility of HDFN due to anti-D.
      • HDFN Due to Other Antibodies
      • Phototherapy helps to prevent which symptom of HDFN?
      • For which of the following antibodies is the DAT most likely to be negative when testing a newborn for possible HDFN?
      • Kernicterus due to high levels of unconjugated bilirubin can cause brain damage in newborns suffering from severe HDFN.
  • Fetal Monitoring and HDFN Treatments
      • Fetal Monitoring
      • Prenatal Treatment
      • Choosing Donor RBC for IUT and IVT
      • Postnatal Treatment: Exchange Transfusion
      • Criteria for Transfused Red Blood Cells
      • Other Postnatal Treatment
      • All of the following criteria for donor RBC to be used for an exchange transfusion relate to both ABO HDFN and HDFN due to anti-D:Less than or equal t...
      • Which procedure used to obtain a fetal blood sample to monitor severity of HDFN can also be used to deliver intravenous transfusions?
  • Perinatal Testing Programs
      • Introduction
      • HDFN Diagnosis and Management
      • Newborn Serologic Testing Protocols
      • Molecular Genotyping
      • Molecular Genotyping: Differentiating Between Weak D and Partial D
      • Determining Risk for HDFN Using Molecular Genotyping
      • For which of these reasons would a molecular method be used to determine a pregnant woman's Rh type?
      • An Rh negative pregnant female has produced anti-D and the physician has decided to use molecular typing to determine if the fetus is at risk. Is the ...
      • Follow-up Investigative Tests (Mother)
      • Follow-up Investigative Tests (Father)
      • Follow-up Investigative Tests (Fetus)
      • Follow-up Investigative Tests (Newborn)
      • Maternal antibody titer is a reliable indicator of fetal disease.
  • Review of Rh Immune Globulin
      • RhIG Prophylaxis
      • RhIG Uses
      • RhIG and Variants of D
      • RhIG Policies for Weak D
      • Clinical Relevance of D Phenotypes
      • RhIG 'Failures'
      • Passive Anti-D following RhIG Administration
      • Protocols to Deal with RhIG-Derived Anti-D
      • When given during pregnancy, RhIG may cross the placenta and sensitize fetal D-positive RBCs.
      • Ectopic pregnancy is an indication for administering RhIG to an Rh negative woman.
      • A Rh positive individual has produced an anti-D antibody. Which D variant possesses the ability to stimulate this production of anti-D? (Choose all th...
      • What dose of RhIG can suppress immunization of 30 mL of D-positive whole blood?
  • Post-delivery Testing of RhIG Candidates
      • Introduction
      • Screening for Fetomaternal Hemorrhage (FMH)
      • Rosette Test
      • Quantifying FMH
      • Kleihauer-Betke (KB) Test
      • Flow Cytometry
      • Calculating RhIG Dosage
      • Which of the following tests are suitable for quantifying the size of fetomaternal hemorrhage (FMH)? Select all that apply.
      • A rosette test may be FALSELY POSITIVE if the mother is weak-D positive.
      • The appropriate dosage of Rh immune globulin (RhIG) to administer post-delivery to an Rh-negative mother delivering an Rh-positive child is calculated...
  • Summary and Conclusions
      • Main Learning Goals
  • Further Reading
      • Resources
  • References
      • References

Additional Information

Level of instruction: Intermediate

Intended Audience: Clinical laboratory technologists, technicians, and pathologists. This course is also appropriate for clinical laboratory science students and pathology residents.
 
Author information:
 
Pat Letendre, MEd is a laboratory technologist, educator, and consultant. Currently, she consults full-time in the areas of transfusion medicine, education, professional development, and use of the Internet in education. Ms. Letendre is the Webmaster for Canada's transfusion safety officers and the TraQ website coordinator. She holds a Masters of Education degree in adult education from the University of Alberta and a Bachelor of Science degree from the University of Manitoba.  
   
Reviewer information:

Erin Tretter, MT(ASCP), is currently the STAT Laboratory Supervisor at Penn Presbyterian Medical Center in Philadelphia, PA. She received her BS in Medical Technology from California University of Pennsylvania and has nearly 8 years of experience as a Generalist, including Blood Bank, Hematology and Chemistry. Erin is the Blood Bank Clinical Instructor for the Clinical Laboratory Science Program at St. Christopher’s and has 4 years experience teaching immunohematology concepts and laboratory procedures to Medical Technology students. She has also provided blood bank training for laboratory technologists and medical students. Erin is currently obtaining a Master’s in Business Administration from Florida Institute of Technology where she is a member of the Phi Kappa Phi Honor’s Society.

Course information:

This course will:

  • Recap relevant background information on HDFN and its treatment
  • Review the characteristics and uses of Rh immune globulin (RhIg)
  • Discuss typical laboratory findings and their interpretations
  • Examine current best practices in perinatal testing programs

It is a companion course to "Rh negative female with anti-D at delive

Hemolytic Disease of the Fetus and Newborn Keywords

These are the most common topics and keywords covered in Hemolytic Disease of the Fetus and Newborn:

physician hemoglobin genotype pubs hemolysis heterozygous antigen-negative anti-a antepartum amniocentesis liver rosette transfused antigen-specific anti-b glucuronyl gene harmless anti-k genotyping jaundice laboratory ectopic immunization ivts umbilical villus anti-e concentration mmol neonatal sensitize titer rhce fresher immunogenic platelet leukoreduced allele decimal down-regulation safety appears cerebral utero procedures rh-negative serum crossmatched heart transfusion intravenous management prophylaxis symptoms pregnancies antibodies titration kell investigative postnatal fat-rich cell-free placenta donor bleeds clinical blood ultrasonography immunized antibody oxygen fathers dats anemia reconstituted agglutination cells epitopes fetal cytometry post-delivery antigens fetomaternal vial amniotic fluid sonography exposure trauma kleihauer-betke prescribed fetal-maternal abdominal gestational soluble transfusions anti-d bilirubin fetus rbcs plasma cells caucasians phototherapy donors immune tamul alleles irradiated previa iuts contains medicine bringing kernicterus survey guidelines doubling hydrops graft-versus-host identification d-positive symptom diagnose extensively enzyme hypoxia-induced protocols rhigs hemorrhage perinatal globulin transferase methods rh-positive reagents brain excretable water-soluble complements newborn anti-fya pregnant dcece diagnosis phenotypes genetics plasma gestation antenatal phenotype cordocentesis sensitivity disease doppler antenatally homozygous hdfn inject dosage antibody-sensitized treatment diagnosing vials immunohematology pregnancy diagnostic fetuses rigor d-negative hyperbilirubinemia samples antiglobulin hematocrit capillaries assessment percutaneous prenatal combinations elution reticulocyte red blood cells hemolytic antigen intrauterine serologic chorionic



Just one user? Visit LabCE.com for individual subscriptions.
Primary vs secondary immune response


BK-Pos arrows


p19 table